Viral hepatitis in Albania, Bosnia and Herzegovina, Montenegro, North Macedonia and Serbia

Marcelo C M Naveira


WHO Consultant (Viral Hepatitis)
TB, HIV/AIDS, Hepatitis and other infectious diseases unit
Division of Country Health Programmes (CHP)






Immunization coverage


HepB BD (given within 24hrs of birth)



HepB3



DTP3




Total burden of disease

Hepatitis B (deaths per 100,000)



Hepatitis C (deaths per 100,000)



Strategic Direction 3: Impact targets

Indicator	Albania	Bosnia and Herzegovina	Montenegro	North Macedonia	Serbia
HBsAg prevalence in vaccinated cohorts Baseline 2020: N/A Interim 2025 targets: 0.50%	0.00% 1.7 (1.1-2.6) (2019)	0.01% 5.0 (3.3-7.2) (2019)	0.01% 5.2 (3.2-7.6) (2019)	0.01% 4.2 (2.7-6.2) (2019)	0.28% 3.1 (1.8-4.7) (2019)
Number of new Hepatitis B infections per year Baseline 2020: 19,000 (20 per 100,000) Interim 2025 targets: 10,500 (11 per 100,000)	2.96 (n=83) (ISHP, 2019)	0.8 (n=19) (ZZJZFBIH, 2020)	0.3 (n=5) (IPH, 2021)	1.4 (n=29) (IPH, 2021)	1.25 (n=87) (IZJZS, 2019)
Number of new Hepatitis C infections per year Baseline 2020: 300,000 (62 per 100,000) Interim 2025 targets: 65,000 (13 per 100,000)	0.64 (n=18) (ISHP, 2019)	0.4 (n=10) (ZZJZFBIH, 2020)	0.2 (n=1) (IPH, 2021)	0.1 (n=3) (IPH, 2021)	0.33 (n=23) (IZJZS, 2019)
Number of new HCV infections among PWID/yr Baseline 2020: 8 per 1,000 Interim 2025 targets: 3 per 1,000	Not known	Not known	Not known	Not known	Not known
Number of deaths due to Hepatitis B per year Baseline 2020: 43,000 (10 per 100,000) Interim 2025 targets: 28,000 (7 per 100,000)	4.5	6.3	3.5	5.7	4.6
Number of deaths due to Hepatitis C per year Baseline 2020: 64,000 (5 per 100,000) Interim 2025 targets: 53,000 (3 per 100,000)	5.3	7.9	4.0	6.5	6.6

Strategic Direction 3: Coverage targets

Indicator	Albania	Bosnia and Herzegovina	Montenegro	North Macedonia	Serbia
Percentage of people living with HBV Dx/Tx Baseline 2020: 19%/2% Interim 2025: 60%/50%	? / ? / 2602* (MTU, 2022)	?/?/~380* (2021)	? / ? / 60 (IPH, 2022)	? / 592 / 535±50 (IPH, 2017) (2022)	? / ? / 2000 (2022)
Percentage of people living with HCV Dx/Tx Baseline 2020: 24%/8% Interim 2025: 60%/50%	? / ? / 294* (MTU, 2022)	? / No waiting list* 960 (DAAs) + 727 IFN (2021)	~2,000 / 354 / >114 (DAAs) + 68 IFN (KCCG, 2018) (IPH, 2022)	? / 1,279 / 259 (DAAs) + 459 IFN* (IPH, 2017) (2022)	? / ? / 5,500 (2022)
Vaccination coverage: HepB3 Baseline 2020: 91% Interim 2025: 95%	98%	80%	52%	79%	87%
% of pregnant women screened for HBsAg Baseline 2020: 91% Interim 2025: 95%	NK (antenatal % high)	NK	Recommended (antenatal % unclear)	NK	NK
% of newborns who received timely HepB-BD Baseline 2020: >90% Interim 2025: 90%	99%	N/A	N/A	97%	99%



Strategic Direction 3: Coverage targets

Indicator	Albania	Bosnia and Herzegovina	Montenegro	North Macedonia	Serbia
Percentage of blood units screened for bloodborne diseases Baseline 2020: 95% Interim 2025: 100%	100%	Not known	100%*	100%*	100%*
Percentage of injections in health care settings undertaken with safe injecting equipment Baseline 2020: No data Interim 2025: 95%	Not known	Not known	Not known	Not known	Not known
Minimum sterile injection equipment kits distributed per person per year for people who inject drugs, as part of a comprehensive package of harm-reduction services Baseline 2020: 200 Interim 2025: 200	42 (2019)	130 (2014)	74 (2020)	66 (2019)	2 (2018)
Percentage of opioid-dependent people who inject drugs who receive OST Baseline 2020: No data Interim 2025: 40%	11.2% (2019) 13-32% (2017) 6 sites	17% (61% among registered) 12 sites	Coverage unclear 5 sites	30.6% (2019) 16 sites	28.3% (2018) 23 sites



Strategic Direction 3: Supportive environment targets

Indicator	Albania	Bosnia and Herzegovina	Montenegro	North Macedonia	Serbia
% of countries that have a costed plan to eliminate hepatitis B and C with measurable targets and indicators Baseline 2020: 33 Interim 2025: 42 (80%)	No	No	Hepatitis response is contained in HIV NSP	No	No
% of countries with burden of disease estimates and annual or every 2 years reporting of the cascade of care Baseline 2020: 36 (70%) Interim 2025: 40 (75%)	Not known	Not known	Not known	Not known	Not known
Integration: % of PLWHIV tested/cured HCV Baseline 2020: No data Interim 2025: 60%/50%	Not known	Not known	100% Tx/Dx (2019)	Not known	Not known



Modelled estimates (CDAF, 2021)



	Indicator	Albania	Bosnia and Herzegovina	Montenegro	North Macedonia	Serbia
Impact	Number of new Hepatitis B infections per year Baseline 2020: 19,000 (20 per 100,000) Interim 2025 targets: 10,500 (11 per 100,000)	40.0 (n=1,100)	50.0 (n=1,500)	8.0 (n=50)	16.0 (n=330)	14.0 (n=1,000)
	Number of new Hepatitis C infections per year Baseline 2020: 300,000 (62 per 100,000) Interim 2025 targets: 65,000 (13 per 100,000)	17.0 (480)	17.0 (540)	17.0 (100)	17.0 (340)	17.0 (1,100)
	Number of deaths due to Hepatitis B per year Baseline 2020: 43,000 (10 per 100,000) Interim 2025 targets: 28,000 (7 per 100,000)	20.0 (680)	10.0 (330)	7.0 (40)	6.0 (130)	7.0 (490)
	Number of deaths due to Hepatitis C per year Baseline 2020: 64,000 (5 per 100,000) Interim 2025 targets: 53,000 (3 per 100,000)	4.0 (110)	4.0 (120)	4.0 (20)	4.0 (80)	4.0 (260)
Coverage	Percentage of people living with HBV Dx/Tx Baseline 2020: 19%/2% Interim 2025: 60%/50%	4.0% / 0.1%	4.0% / 0.8%	20.0% / 2.0%	20.0% / 2.0%	20.0% / 1.0%
	Percentage of people living with HCV Dx/Tx Baseline 2020: 24%/8% Interim 2025: 60%/50%	18.0% / 1.0%	18.0% / 1.0%	18.0% / 1.0%	18.0% / 1.0%	18.0% / 1.0%

WHO & Partners - Acknowledgements

- World Hepatitis Alliance
- National counterparts and health workforce
- CDA Foundation
- European Association for the Study of the Liver
- European Centre for Disease Prevention and Control
- US Centers for Disease Prevention and Control
- Viral Hepatitis Prevention Board
- WHO Collaborating Centres
 - Robert Koch Institute (DEU)
 - National Center for Disease Control and Public Health (GEO)



